Karen Reckamp, MD, MS, Named Medical Director for Clinical Research Operations at City of Hope


Get Permission

Karen Reckamp, MD, MS

Medical oncologist and lung cancer researcher Karen Reckamp, MD, MS, has been named Medical Director for Clinical Research Operations at City of Hope. In this newly created position, Dr. Reckamp will expand her current role as Chair of the Cancer Protocol Review and Monitoring Committee, in which she has been instrumental in supporting and shaping the regulatory, operational, and scientific directives of the clinical research mission of City of Hope. As Medical Director, she’ll serve as Medical Advisor for Clinical Research Operations, as Medical Director of the Clinical Trials Unit, and as Coordinating Liaison for pharmaceutical contracts. She will also share responsibility for the review and selection of clinical trials within City of Hope. 

“Dr. Reckamp has shown remarkable leadership as City of Hope moves to launch a new era of scientific research and lifesaving clinical trials,” said ­Larry W. Kwak, MD, PhD, Associate Director for Developmental Therapeutics and Translational Research at City of Hope and Director of the Toni Stephenson Lymphoma Center. “Her deep knowledge of the complex regulatory and operational aspects of City of Hope’s clinical trials has been, and will continue to be, invaluable as we rapidly turn breakthrough research into new treatments and cures.”

Nationally known for her clinical research expertise, Dr. Reckamp is also Co-Chair of the institution’s Lung Cancer and Thoracic Oncology Program, helping expand options for people diagnosed with lung cancer. She is currently principal investigator for an arm of the National Cancer Institute’s NCI-Molecular Analysis for Therapy Choice, known as the NCI-MATCH trial.   

Dr. Reckamp joined City of Hope in 2007 as Assistant Professor of Medicine in the Department of Medical Oncology & Therapeutics. In 2012, she became Associate Professor in the Department of Medical Oncology & Therapeutics Research, and Codirector of the Lung Cancer and Thoracic Oncology Program. ■



Advertisement

Advertisement



Advertisement